Boilerplate clauses

Copyright © 2025 LexisNexis

This subtopic focuses on boilerplate clauses in commercial business-to-business agreements. For information on commercial clauses more generally, see: Commercial clauses—overview.

For information on boilerplate in business-to-consumer contracts, see the section on ‘Consumer boilerplate’ below.

For information on boilerplate in public sector contracts, see the section on ‘Public sector boilerplate’ below.

The role of boilerplate

Lawyers work on a huge variety of transactions, but all of them will in some way involve written agreements. All of those agreements should contain some boilerplate clauses.

‘Boilerplate’ is the term used to describe the clauses that are included in an agreement to deal with the mechanics of how it works and those legal points that are relevant to most transactions. For further consideration of the role and importance of boilerplate clauses, see Practice Note: The role of boilerplate.

Boilerplate clauses are generally found at the beginning and the end of an agreement. Such clauses are often thought of as standard, miscellaneous provisions, but this is a very dangerous view to adopt. It is not unusual for a boilerplate clause to be the cause of litigation. Since a boilerplate clause

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Existing user? Sign-in TAKE A FREE TRIAL
Powered by Lexis+®
Latest Life Sciences News

MHRA dismantles first illicit weight loss medicine production facility in UK

The Medicines and Healthcare products Regulatory Agency (MHRA) Criminal Enforcement Unit has raided a warehouse in Northampton, seizing over 2,000 unlicensed retatrutide and tirzepatide injection pens valued at over £250,000, along with tens of thousands of empty pens and manufacturing equipment. The two-day operation, supported by Northamptonshire Police, also recovered £20,000 in cash suspected of being linked to medicines trafficking.

DSIT announces measures to reduce regulatory barriers to innovation

The Department for Science, Innovation and Technology (DSIT), working with bodies including the Medicines and Healthcare products Regulatory Agency (MHRA), Environment Agency, Care Quality Commission, and others, has announced measures to reduce regulatory barriers that have delayed the deployment of innovative technologies. The reforms aim to create a more pro-innovation regulatory environment to support technologies such as drones delivering medicines and artificial intelligence (AI) tools for faster clinical approvals. An £8.9m funding package, delivered through the Regulatory Innovation Office (RIO), is intended to support 16 projects that will help regulators and industry trial more agile approaches to innovation.

MHRA announces AI-driven project to predict drug interaction side effects

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced a new project aimed at predicting side effects from drug combinations before they reach patients. The initiative is supported by £859,650 in funding from the UK Government’s Regulatory Innovation Office through its AI Capability Fund. The project will apply AI to anonymised NHS data to identify patterns in how cardiovascular medicines interact when prescribed together. These signals will be validated in laboratory settings using human-based models that simulate drug metabolism. The MHRA states that the goal is to develop a tool that supports safer and more effective prescribing practices.

Life Sciences weekly highlights—23 October 2025

This week's edition of Life Sciences weekly highlights includes news on the UK Administrative Court’s decision to dismiss a judicial review challenging a refusal to be included in the pharmaceutical list for distance selling premises (R (Medis Pharma) v NHS Resolution), the European Commission adopted its sixth and final implementing regulation for joint clinical assessments of medical devices under the Health Technology Assessment Regulation, and the MHRA selected seven AI healthcare technologies for the second phase of its AI Airlock regulatory sandbox programme. Also included, is news that the European Parliament’s Environment, Public Health and Food Safety (ENVI) Committee will vote on its draft opinion regarding environmental aspects of the Commission’s Critical Medicines Act following 119 tabled amendments, the EMA updated its FAQ guidance document on parallel distribution, the European Commission adopted its 2026 Work Programme, the DHSC and NHS England published positive time-saving findings from the world’s largest healthcare AI trial and the UK government announced a funding boost for regional science and technology sectors, among other stories.

View Life Sciences by content type :  
News
Practice notes
Precedents
Q&As

Popular documents

Priority between loss reliefs in loss making companies

Priority between loss reliefs in loss making companiesWhy does it matter?A company that is a member of a group and has incurred any of the types of losses available for surrender by way of group relief may, without any further rules, have more than one way in which to use the loss. There are a

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?What is an appeal?An appeal in insolvency proceedings is no different to an appeal in normal litigation. An appeal will be allowed only if the appeal court is satisfied that the decision of the lower court was 'wrong' or 'unjust because of a

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an
Priority between loss reliefs in loss making companies

Priority between loss reliefs in loss making companies

Priority between loss reliefs in loss making companiesWhy does it matter?A company that is a member of a group and has incurred any of the types of losses available for surrender by way of group relief may, without any further rules, have more than one way in which to use the loss. There are a

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?What is an appeal?An appeal in insolvency proceedings is no different to an appeal in normal litigation. An appeal will be allowed only if the appeal court is satisfied that the decision of the lower court was 'wrong' or 'unjust because of a

Contributory negligence in personal injury claims

Contributory negligence in personal injury claims

Contributory negligence in personal injury claimsContributory negligence is a partial defence which can lead to a discount in damages.Other defences may also be relevant. See Practice Notes: Did the claimant consent to the risk of injury? and Was the claimant involved in an illegal activity?If a

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an